Loading, please wait...
|
LINK TO EVALUATION >> (opened after session) |
PARKING REQUEST FORM » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Tuesday, October 11, 2022
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
Link to Teams Meeting
|
||||
|
SESSION 1
1:00 – 1:45
|
Valerie Yuenger, PharmD
Contemporary Review of Azole Antifungals for the Primary Treatment of Invasive Pulmonary Aspergillosis
|
Kelsey Olion, PharmD
Therapeutic Drug Monitoring of β-lactam Antibiotics: Is It REALLY Necessary?
|
Melia Burns, PharmD
Subcutaneous Insulin in the Setting of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome
|
Ellie Nazzoli, PharmD
Asthma Guideline Updates and the Role of Biologics
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40
|
Renae Scott, PharmD
Treatment of Persistent MRSA
Bacteremia
|
Mikaela McCabe, PharmD
Frontline Therapy for High Grade Diffuse Large B-Cell Lymphoma
|
Cassidy Hays, PharmD
Efficacy and Safety of Aducanumab in Alzheimer's Disease
|
Molly Jorns, PharmD
Antibiotic Prophylaxis in Type III
Open Fractures
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:35
|
Maria Gorla, PharmD
Anticoagulation in Patients with Gastrointestinal Cancers
|
Jason Votrain, PharmD
Cancer, Cardiovascular and Other Risks of Tofacitinib Use in Rheumatoid Arthritis Patients with Cardiovascular Risk Factors
|
Lauren Hetzler, PharmD
Tenecteplase vs. Alteplase for Acute Ischemic Stroke
|
Nikolas Dotolo, PharmD
Pushing the Limits of Pediatric Shock: Going Beyond the Guidelines |
Please join us for the first Resident Seminar session of the 2022-2023 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in classrooms in the Academic & Research Building (ARB) on the third floor (see classroom numbers above), as well as virtually (see Teams links above).
Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned for this Resident Seminar is 2.25 contact hours. Participants must complete an evaluation (see link above) to receive credit.
Click here for a printable copy of the schedule
REGISTRATION: To register for the LIVE Resident Seminar presentations, click here>>>. There is no need to register for the virtual presentations. Please use the links within the table above to connect to the VIRTUAL presentations. Special note, this event has multiple concurrent sessions.
Due to a limited number of live available classroom spaces, a maximum of 30 people are allowed per classroom. Virtual attendance is limitless.
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, October 7, 2022 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Participants attending the LIVE (on-campus) sessions will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the conversation feature within Teams. Copies of PowerPoint slides are not provided.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy in St. Louis is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close October 18, 2022 at 11:59 PM (CST).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Learn more! Click the + symbol below to expand.
Date: Oct 11, 2022 01:00 PM - 03:35 PM
Fee
$0.00
CE Hours
9.00
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Invasive aspergillosis (IA) is the most devastating form of disease caused by Aspergillus, which most often manifests as invasive pulmonary aspergillosis (IPA). IPA occurs primarily in patients with clinically significant immunosuppression, especially those with hematologic malignancies, recipients of allogeneic hematopoietic stem cell transplants or solid organ transplants, and/or receipt of immunosuppressive therapies. Despite a significant decrease following the introduction of mold-active azole antifungal therapies, the 6-week mortality rate of IPA has remained stable around 20%, with 1-year mortality rates still approaching 50%. Most current guidelines recommend voriconazole as the first-line primary treatment, isavuconazole as an alternate first-line primary treatment, and posaconazole as a salvage treatment option. Treatment often requires prolonged durations of several weeks to months and may be limited by the tolerability of these agents. While some safety and tolerability concerns are overlapping among agents in the azole drug class, many adverse events and drug-drug interactions are more common with certain azoles. Evidence published following many of the guideline updates demonstrated noninferior efficacy and improved safety and tolerability of isavuconazole and posaconazole. This seminar will review the contemporary literature evaluating the efficacy and safety of azole antifungals for the primary treatment of IPA, with a focus on patient and infection factors to consider in selecting optimal azole antifungal therapy.
Objectives
- Summarize the literature describing the safety and efficacy of azole antifungal therapies for the primary treatment of invasive pulmonary aspergillosis (IPA).
- Identify patient and infection characteristics pertinent in the selection of optimal azole antifungal therapy for the primary treatment of IPA.
Speaker(s)/Author(s)
|
Valerie Yuenger, Pharm.D. |
Activity Number
0033-0000-22-015-L01-P
Date:
10/11/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304 and Virtually
With β-lactam antibiotics being time-dependent killers, the time that their concentration remains above the minimum inhibitory concentration (MIC) of a targeted pathogen is the best predictor of antibacterial effect. Since pharmacokinetic and pharmacodynamic properties vary greatly between and even within patients during acute illness, tailoring β-lactam regimens through the use of therapeutic drug monitoring (TDM) is a potential solution.
Studies have shown that β-lactam concentrations are often suboptimal in critically ill patients, though how this translates to clinical outcomes is unclear. This presentation will discuss the rationale behind therapeutic drug monitoring for β-lactam antibiotics, review related evidence, identify barriers associated with the implementation of this practice, and provide guidance for conducting TDM in specific patient populations when appropriate.
Objectives
- Name the PK/PD index that best predicts target attainment for ?-lactamantibiotics.
- Describe the conclusions made in recent publications related to ?-lactam TDM.
- Describe a patient for which ?-lactam TDM would be appropriate to consider.
Speaker(s)/Author(s)
|
Kelsey Olion, Pharm.D. |
Activity Number
0033-0000-22-014-L01-P
Date:
10/11/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This presentation will focus on two complications of diabetes mellitus - diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar syndrome (HHS). Institutions routinely use continuous intravenous (IV) regular insulin for treatment, requiring intensive care unit (ICU) status; however, subcutaneous rapid-acting insulin analogs in a non-intensive care unit (ICU) setting have been shown to be as safe and effective as intravenous regular insulin in the ICU. This presentation will discuss the differences between continuous intravenous regular insulin therapy and subcutaneous rapid-acting insulin analog therapy in treating hyperglycemic crises. This presentation will review the American Diabetes Association (ADA) guidelines with the goal of reviewing literature supporting subcutaneous management of DKA/HHS in certain patient populations.
Objectives
- Identify blood glucose and hemoglobin A1c goals for adults with diabetes mellitus.
- Define characteristic symptoms of diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar syndrome (HHS).
- Identify patients where subcutaneous insulin therapy could be utilized.
- Identify guideline recommendations in treating DKA/HHS.
Speaker(s)/Author(s)
|
Melia Burns, Pharm.D. |
Activity Number
0033-0000-22-021-L01-P
Date:
10/11/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354 and Virtually
This presentation will provide an overview of the 2019 and 2021 updates to the GINA guidelines and cover the literature that went into the guideline changes. Next, this presentation will dive in to the newly approved asthma medications, focusing on biologics. After a overall review of biologics currently on the market for asthma, the presentation will focus in on tezepelumab, looking at the primary literature and cost-effectiveness of the medication. After this presentation, pharmacists should be able to have a better understanding of the rationale behind the guideline changes and be able to use those updates in their recommendations to providers. They should also be able to make informed recommendations to other professionals and patients about the use of biologics for asthma.
Objectives
- Discuss the updates to the Global Initiatives for Asthma guidelines.
- Compare and contrast the currently approved biologics for asthma.
- Describe tezepelumab's place in therapy for asthma management.
Speaker(s)/Author(s)
|
Ellie Nazzoli, Pharm.D. |
Activity Number
0033-0000-22-023-L01-P
Date:
10/11/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355 and Virtually
The recognition and treatment of persistent MRSA bacteremia will be discussed in this seminar.There will be a review of current guidelines and evaluation of recent literature which has provided new insight into identification and treatment of this common yet complex disease state. The focus of this presentation will be to develop a defintion of persistent MRSA bacteremia and to discuss the ideal antibiotic regimens for its treatment based on published research. Questions incorporating materials discussed during the presentation will be used as teaching materials throughout the seminar.
Objectives
- Define persistent MRSA bacteremia.
- Identify an appropriate treatment plan for persistent MRSA bacteremia.
- Identify appropriate duration of antibiotic therapy in persistent MRSA bacteremia.
Speaker(s)/Author(s)
|
Renae Scott, Pharm.D. |
Activity Number
0033-0000-22-018-L01-P
Date:
10/11/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304 and Virtually
This seminar will introduce the audience to background information, biological features, and treatment considerations for high grade diffuse large B-cell lymphoma (DLBCL). The current National Comprehensive Cancer Network treatment guidelines for this specific patient population remain vague and the optimal treatment is unclear. This seminar will explore various treatment options, expert opinions, and future directions for the treatment of high grade DLBCL to better elucidate current data.
Objectives
- Identify the biological features that define double-hit, triple-hit, double-expressor, and triple-expressor diffuse large B-cell lymphoma.
- Describe the outcomes of pertinent trials for the treatment of high grade DLBCL after being presented with a patient case.
Speaker(s)/Author(s)
|
Mikaela McCabe, Pharm.D. |
Activity Number
0033-0000-22-016-L01-P
Date:
10/11/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305 and Virtually
Alzheimer's disease is a serious affliction that can rapidly progress leading to a decrease in cognitive function. A hypothesized etiology of Alzheimer's disease is the aggregation of amyloid-beta plaques in the brain. A recently FDA approved medication, aducanumab, has shown efficacy by preventing amyloid-beta plaque aggregation. By preventing plaque aggregation, disease progression can be slowed, potentially leading to a higher quality of life for patients. Limited data has been published on the phase 3 trials so navigating patient criteria and implementing medication regimens may pose a challenge.
Objectives
- Describe current treatment algorithms for Alzheimer's disease.
- Explain the proposed mechanism of action of aducanumab.
- Identify patient eligibility for aducanumab.
- Identify a treatment plan for initiation and monitoring of aducanumab.
Speaker(s)/Author(s)
|
Cassidy Hays, Pharm.D. |
Activity Number
0033-0000-22-022-L01-P
Date:
10/11/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354 and Virtually
Open fractures are a major source of morbidity and mortality associated with trauma. Use of systemic antibiotics in this population has been shown to decrease infection rates and are a part of standard treatment. However, controversy exists over optimal antibiotic prophylaxis, in particular for type III open fractures. Use of broad-spectrum antibiotics for prophylaxis poses risks including acute kidney injury with aminoglycosides, antimicrobial resistance, and superinfections with multidrug-resistant organisms. Despite risks associated with broad-spectrum agents, many trauma centers continue to use these agents. This continuing education seminar will evaluate relevant literature and optimal antibiotic prophylaxis choices for type III open fractures.
Objectives
- Describe classification of and common pathogens associated with type III open fractures.
- Identify appropriate antibiotic timing, including initiation and discontinuation, in open fractures.
- Select an appropriate prophylactic antibiotic regimen in patients with type III open fractures.
Speaker(s)/Author(s)
|
Molly Jorns, Pharm.D. |
Activity Number
0033-0000-22-020-L01-P
Date:
10/11/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355 and Virtually
This presentation seeks to describe guideline recommendations and data surrounding the use of direct oral anticoagulants in cancer-associated venous thromboembolism, specifically as it pertains to gastrointestinal cancers. At the end of this presentation, the audience should be able to describe caveats for the use of direct oral anticoagulants in gastrointestinal cancers.
Objectives
- Summerize guideline recommendations and data surrounding the use of direct oral anticoagulants in cancer-associated venous thromboembolism.
- Describe data surrounding the use of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism, specifically as it pertains to gastrointestinal cancers
- Summarize caveats for the use of direct oral anticoagulants in gastrointestinal cancers.
Speaker(s)/Author(s)
|
Maria Gorla, Pharm.D. |
Activity Number
0033-0000-22-025-L01-P
Date:
10/11/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 304 and Virtually
Patients with rheumatoid arthritis (RA) account for around 1% of the population. Due to the pathophysiology of the disease, these patients are at an increased risk of having major adverse cardiovascular events (MACE). This presentation aims to discuss the pathophysiology of RA, the available guideline-recommended pharmacologic treatments, and analyze the emerging safety data surrounding a second-line RA treatment option, tofacitinib (Xeljanz). The focus of the presentation will be on tofacitinib and will analyze studies that focus on its safety profile. These newer safety trials were prompted by the FDA after post-marketing data exposed that tofacitinib users may be at an increased risk of developing cancers, VTEs and higher lipid levels. This data may prove to alter guideline recommendations in favor of one second line drug class versus another and potentially change the current prescribing habits of tofacitinib.
Objectives
- Describe the role of tofacitinib in the treatment of rheumatoid arthritis.
- Indicate guideline-driven therapy options for patients with rheumatoid arthritis.
- Select patients that may be at an increased risk of developing a major adverse cardiovascular event if treated with tofacitinib.
Speaker(s)/Author(s)
|
Jason Votrain, Pharm.D. |
Activity Number
0033-0000-22-017-L01-P
Date:
10/11/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 305 and Virtually
Clinical controversy exists over the optimal fibrinolytic agent for treatment of acute ischemic stroke. Alteplase is the only FDA approved fibrinolytic for acute ischemic stroke and has been the mainstay of therapy since approval in 1996. Tenecteplase, a modified version of alteplase, offers pharmacologic and logistical advantages such as a longer half-life without the need for a continuous infusion. The recent 2019 AHA/ASA Guideline Update for the Management of Acute Ischemic Stroke includes a Level B recommendation that it may be reasonable to use tenecteplase over alteplase for thrombolysis in patients who are also eligible to undergo mechanical thrombectomy. Since guideline publication, additional literature suggests that tenecteplase may be noninferior to alteplase in terms of efficacy with no differences in safety. The purpose of this presentation is to analyze available literature comparing the two agents for treatment of acute ischemic stroke and subsequently propose recommendations for the agent of choice for thrombolytic therapy.
Objectives
- Describe the pharmacological and practical differences between tenecteplase and alteplase.
- Compare and contrast the safety and efficacy of tenecteplase and alteplase for acute ischemic stroke based on available literature.
- Describe the evidence supporting dosing of tenecteplase for acute ischemic stroke.
Speaker(s)/Author(s)
|
Lauren Hetzler, Pharm.D. |
Activity Number
0033-0000-22-019-L01-P
Date:
10/11/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 354 and Virtually
This continuing pharmacy education lecture will focus on the management of pediatric septic shock and expanding the recommendations of the pediatric surviving sepsis guidelines. The pathophysiology of septic shock will be discussed, in addition to the literature supporting guideline recommendations and additional therapies beyond the scope of the guidelines. By the end of the presentation, the audience will be able to appropriately manage the hemodynamics of septic shock using a patient specific approach.
Objectives
- Discuss the pathophysiology and initial management of septic shock.
- Identify an appropriate vasopressor regimen in a pediatric patient.
Speaker(s)/Author(s)
|
Nikolas Dotolo, Pharm.D. |
Activity Number
0033-0000-22-024-L01-P
Date:
10/11/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 355 and Virtually
